ReviewFrontiers in immunology2018
Current Status of Gene Engineering Cell Therapeutics.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Immune reconstruction after allogeneic hematopoietic stem cell transplantation: rules, mechanisms, and applications.Annals of hematology · 2026Review
- Imaging of T-cell Responses in the Context of Cancer Immunotherapy.Cancer immunology research · 2021Review
- Article
- Cellular immunotherapies for cancer.Irish journal of medical science · 2021Review
- Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.Stem cells translational medicine · 2020Review
- Review
- Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Review
- The clinical potential of gene editing as a tool to engineer cell-based therapeutics.Clinical and translational medicine · 2020Review
- Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time.CPT: pharmacometrics & systems pharmacology · 2020Article
- The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.Frontiers in immunology · 2020Review
- How Non-invasiveFrontiers in physiology · 2020Review
- Future prospects for CD8Immunological reviews · 2019Review
- Imaging of T-cells and their responses during anti-cancer immunotherapy.Theranostics · 2019Review
- T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.Cell death & disease · 2019Article
- Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.Molecular therapy. Methods & clinical development · 2019Review
- Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells.Frontiers in immunology · 2019Article
- Cousins at work: How combining medical with optical imaging enhances in vivo cell tracking.The international journal of biochemistry & cell biology · 2018Review
- Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.